C07J 41/0005
The nitrogen atom being directly linked to the cyclopentahydro phenanthrene skeleton
Official title: {the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton}
C07J41/0005 (The nitrogen atom being directly linked to the cyclopentahydro phenanthrene skeleton) appears on 475 US grants and 308 published applications in this corpus.
Search patents in C07J- Granted patents
- 475
- Published applications
- 308
- Assignees
- 249
- Inventors
- 915
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 6 | 0 |
| 1978 | 11 | 0 |
| 1979 | 4 | 0 |
| 1980 | 19 | 0 |
| 1981 | 7 | 0 |
| 1982 | 10 | 0 |
| 1983 | 8 | 0 |
| 1984 | 8 | 0 |
| 1985 | 9 | 0 |
| 1986 | 7 | 0 |
| 1987 | 6 | 0 |
| 1988 | 4 | 0 |
| 1989 | 8 | 0 |
| 1990 | 7 | 0 |
| 1991 | 13 | 0 |
| 1992 | 8 | 0 |
| 1993 | 10 | 0 |
| 1994 | 7 | 0 |
| 1995 | 10 | 0 |
| 1996 | 15 | 0 |
| 1997 | 27 | 0 |
| 1998 | 32 | 0 |
| 1999 | 31 | 0 |
| 2000 | 12 | 0 |
| 2001 | 11 | 1 |
| 2002 | 10 | 10 |
| 2003 | 5 | 7 |
| 2004 | 3 | 10 |
| 2005 | 6 | 14 |
| 2006 | 5 | 8 |
| 2007 | 2 | 6 |
| 2008 | 1 | 3 |
| 2009 | 4 | 5 |
| 2010 | 5 | 13 |
| 2011 | 5 | 11 |
| 2012 | 1 | 10 |
| 2013 | 11 | 12 |
| 2014 | 8 | 18 |
| 2015 | 7 | 12 |
| 2016 | 8 | 15 |
| 2017 | 11 | 17 |
| 2018 | 12 | 16 |
| 2019 | 15 | 19 |
| 2020 | 12 | 12 |
| 2021 | 10 | 16 |
| 2022 | 11 | 19 |
| 2023 | 5 | 19 |
| 2024 | 6 | 9 |
| 2025 | 8 | 12 |
| 2026 | 5 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Crystalline forms of squalamine21 Jul 2026US 12,686,699 B2Enterin, Inc.
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- Small molecule modulators of gut bacterial bile acid metabolism17 Mar 2026US 12,577,273 B2President and Fellows of Harvard College
- Chemical structures that control metabolic elimination of aminosterols10 Mar 2026US 12,570,686 B1BAZ Therapeutics, Inc.
- Compounds for use in the treatment of liver disease13 Jan 2026US 12,522,631 B2The Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin
- Aminosterol compounds, aminosterol-cyclodextrin formulations, and methods of using the same10 Sep 2026US 2026/0263485 A1Enterin, Inc.
- 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor10 Sep 2026US 2026/0265290 A1Umecrine Cognition AB
- Antibacterial compounds eliminating dormant bacterial cells27 Aug 2026US 2026/0250312 A1Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Aminosteroids for the Treatment of a PTP1B Associated Disease20 Aug 2026US 2026/0242409 A1Depymed, Inc.
- Catalyst for sp3-carbon-hydrogen-bond primary amination reaction, and method for preparing primary amine compound13 Aug 2026US 2026/0234096 A1West China Second University Hospital, Sichuan University
Most cited
By later US patents
- Oligonucleotide having enhanced binding affinity276US 5,486,603 AGilead Sciences, Inc. · 1996
- Label modified immunoassays229US 4,208,479 ASyva Company · 1980
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983
- Cationic amphiphile/DNA complexes149US 5,948,767 AGenzyme Corporation · 1999
- Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules134US 5,767,099 AGenzyme Corporation · 1998